Cat. No.: HY-111784

Inobrodib

(Synonyms: CCS1477)

12 Cited Publications

고객리뷰

Based on 12 publication(s) in Google Scholar

Inobrodib (CCS1477) is an orally active, potent, and selective inhibitor of the p300/CBP bromodomain. Inobrodib binds to p300 and CBP with K_d values of 1.3 and 1.7 nM, respectively, and with 170/130-fold selectivity compared with BRD4 with a K_d of 222 nM. CCS1477 inhibits cell proliferation in prostate cancer cell lines and decreases androgen receptor (AR)- and C-MYC-regulated gene expression.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Purity: 99.95%
CAS No.: 2222941-37-7
화학식: C₃₀H₃₂F₂N₄O₃
분자량:534.60

보관:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Inobrodib Chemical Structure

CAS No.: 2222941-37-7

사이즈

가격

재고

수량

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- 제품 설명
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (12)
용액&용해도
- In Vitro
- In Vivo
순도&문서
References
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

IC₅₀ & Target

CBP/p300

All Epigenetic Reader Domain Isoforms :

All Histone Acetyltransferase Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
CWR22R	IC₅₀	0.42 μM Compound: 4; CCS1477	Antiproliferative activity against human 22Rv1 cells assessed as cell growth inhibition by Celltiter-Glo assay Antiproliferative activity against human 22Rv1 cells assessed as cell growth inhibition by Celltiter-Glo assay	[PMID: 34962793]
CWR22R	IC₅₀	184 nM Compound: 3; CCS1477	Antiproliferative activity against AR positive human 22Rv1 cells assessed inhibition of cell growth measured after 4 days by CellTiter-Glo Luminescent cell viability assay Antiproliferative activity against AR positive human 22Rv1 cells assessed inhibition of cell growth measured after 4 days by CellTiter-Glo Luminescent cell viability assay	[PMID: 38530938]
CWR22R	IC₅₀	184 nM Compound: 5; CCS1477	Antiproliferative activity against human 22Rv1 cells assessed as cell growth inhibition incubated for 4 days by celtiter-glo luminescent assay Antiproliferative activity against human 22Rv1 cells assessed as cell growth inhibition incubated for 4 days by celtiter-glo luminescent assay	[PMID: 38477974]
EOL1	IC₅₀	<3 μM Compound: 4; CCS1477	Antiproliferative activity against human EOL1 cells Antiproliferative activity against human EOL1 cells	[PMID: 38649304]
Hep 3B2	IC₅₀	1.928 μM Compound: 4; CCS1477	Antiproliferative activity against human Hep3B cells assessed as inhibition of cell proliferation incubated for 6 days by CCK-8 assay Antiproliferative activity against human Hep3B cells assessed as inhibition of cell proliferation incubated for 6 days by CCK-8 assay	[PMID: 39356741]
HepG2	IC₅₀	0.869 μM Compound: 4; CCS1477	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 6 days by CCK-8 assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 6 days by CCK-8 assay	[PMID: 39356741]
KG-1	IC₅₀	<3 μM Compound: 4; CCS1477	Antiproliferative activity against human KG-1 cells Antiproliferative activity against human KG-1 cells	[PMID: 38649304]
KG-1	IC₅₀	17.04 μM Compound: 4; CCS1477	Antiproliferative activity against human KG-1 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter glo luminescence analysis Antiproliferative activity against human KG-1 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter glo luminescence analysis	[PMID: 38829718]
L02	IC₅₀	20 μM Compound: 4; CCS1477	Cytotoxicity against human HL7702 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter glo luminescence analysis Cytotoxicity against human HL7702 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter glo luminescence analysis	[PMID: 38829718]
LNCaP	IC₅₀	0.06 μM Compound: 4; CCS1477	Antiproliferative activity against human LNCaP cells assessed as cell growth inhibition by Celltiter-Glo assay Antiproliferative activity against human LNCaP cells assessed as cell growth inhibition by Celltiter-Glo assay	[PMID: 34962793]
LNCaP	IC₅₀	412 nM Compound: 3; CCS1477	Antiproliferative activity against AR positive human LNCaP cells assessed inhibition of cell growth measured after 4 days by CellTiter-Glo Luminescent cell viability assay Antiproliferative activity against AR positive human LNCaP cells assessed inhibition of cell growth measured after 4 days by CellTiter-Glo Luminescent cell viability assay	[PMID: 38530938]
LNCaP	IC₅₀	412 nM Compound: 5; CCS1477	Antiproliferative activity against human LNCaP cells assessed as cell growth inhibition incubated for 4 days by celtiter-glo luminescent assay Antiproliferative activity against human LNCaP cells assessed as cell growth inhibition incubated for 4 days by celtiter-glo luminescent assay	[PMID: 38477974]
LNCaP C4-2B	IC₅₀	1.65 μM Compound: 4; CCS1477	Antiproliferative activity against human LNCaP C4-2B cells assessed as inhibition of cell growth by Celltiter-Glo assay Antiproliferative activity against human LNCaP C4-2B cells assessed as inhibition of cell growth by Celltiter-Glo assay	[PMID: 34962793]
MOLM-13	IC₅₀	102.5 nM Compound: 4; CCS1477	Antiproliferative activity against human MOLM-13 cells incubated for 72 hrs by Cell-Titer Glo assay Antiproliferative activity against human MOLM-13 cells incubated for 72 hrs by Cell-Titer Glo assay	[PMID: 38649304]
MOLM-16	IC₅₀	0.37 μM Compound: 4; CCS1477	Antiproliferative activity against human MOLM16 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter glo luminescence analysis Antiproliferative activity against human MOLM16 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter glo luminescence analysis	[PMID: 38829718]
MOLM-16	IC₅₀	12.9 nM Compound: 4; CCS1477	Antiproliferative activity against human MOLM16 cells incubated for 72 hrs by Cell-Titer Glo assay Antiproliferative activity against human MOLM16 cells incubated for 72 hrs by Cell-Titer Glo assay	[PMID: 38649304]
MOLT-4	IC₅₀	0.247 μM Compound: 4; CCS1477	Antiproliferative activity against human MOLT-4 cells assessed as inhibition of cell proliferation incubated for 6 days by CCK-8 assay Antiproliferative activity against human MOLT-4 cells assessed as inhibition of cell proliferation incubated for 6 days by CCK-8 assay	[PMID: 39356741]
MV4-11	IC₅₀	0.014 μM Compound: 4; CCS1477	Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 120 hrs by celltiter glo luminescence analysis Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 120 hrs by celltiter glo luminescence analysis	[PMID: 38829718]
MV4-11	IC₅₀	20.4 nM Compound: 4; CCS1477	Antiproliferative activity against human MV4-11 cells incubated for 120 hrs by Cell-Titer Glo assay Antiproliferative activity against human MV4-11 cells incubated for 120 hrs by Cell-Titer Glo assay	[PMID: 38649304]
OPM-2	IC₅₀	30 nM Compound: 4; CCS1477	Antiproliferative activity against human OPM-2 cells assessed as inhibition of cell proliferation incubated for 6 days by CCK8 assay Antiproliferative activity against human OPM-2 cells assessed as inhibition of cell proliferation incubated for 6 days by CCK8 assay	[PMID: 39356741]
RPMI-8226	IC₅₀	0.082 μM Compound: 4; CCS1477	Antiproliferative activity against human RPMI-8226 cells assessed as inhibition of cell proliferation incubated for 6 days by CCK-8 assay Antiproliferative activity against human RPMI-8226 cells assessed as inhibition of cell proliferation incubated for 6 days by CCK-8 assay	[PMID: 39356741]
SK-HEP1	IC₅₀	4.679 μM Compound: 1; CCS1477	Antiproliferative activity against human SK-HEP1 cells assessed as inhibition of cell growth incubated for 5 days by CCK-8 assay Antiproliferative activity against human SK-HEP1 cells assessed as inhibition of cell growth incubated for 5 days by CCK-8 assay	[PMID: 38316017]
THP-1	IC₅₀	<3 μM Compound: 4; CCS1477	Antiproliferative activity against human THP-1 cells Antiproliferative activity against human THP-1 cells	[PMID: 38649304]
VCaP	IC₅₀	195 nM Compound: 5; CCS1477	Antiproliferative activity against human VCaP cells assessed as cell growth inhibition incubated for 4 days by celtiter-glo luminescent assay Antiproliferative activity against human VCaP cells assessed as cell growth inhibition incubated for 4 days by celtiter-glo luminescent assay	[PMID: 38477974]
VCaP	IC₅₀	53.6 nM Compound: 3; CCS1477	Antiproliferative activity against AR positive human VCaP cells assessed inhibition of cell growth measured after 4 days by CellTiter-Glo Luminescent cell viability assay Antiproliferative activity against AR positive human VCaP cells assessed inhibition of cell growth measured after 4 days by CellTiter-Glo Luminescent cell viability assay	[PMID: 38530938]

In Vitro

Inobrodib binding to cellular histones in an in-cell BRET assay gives an IC₅₀ of 19 nM for p300 and 1060 nM for BRD4. Inobrodib shows potent growth-inhibitory activity in VCaP, 22Rv1, and LNCaP95 (all IC₅₀ < 100 nM) that express both AR-FL and AR-V7^[1].
Inobrodib (0-3000 nM; 48 hours) reduces expression of AR-regulated genes (KLK2, KLK3, and TMPRSS2) in both 22Rv1 and LNCaP95 cells. Inobrodib also reduces C-MYC protein expression in both 22Rv1 and LNCaP95 cells and AR-V7 protein expression in 22Rv1 cells, without clear impact on AR-FL protein expression in 22Rv1 and LNCaP95 cells. Inobrodib reduces C-MYC mRNA and downstream AR and C-MYC signaling in 22Rv1 and C4-2 cells at 16 hours. Inobrodib regulates AR signaling by affecting the recruitment of CBP, p300, and AR-FL to known AR binding sites, and has the potential to abrogate persistent AR signaling in CRPC^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Inobrodib (10-30 mg/kg; oral gavage; 10 or 20 mg/kg daily (QD) or 30 mg/kg every other day (QOD) for 28 days) suppresses growth of a 22Rv1 mouse xenograft model with associated reduction in AR signaling^[1].
Inobrodib (20 mg/kg; oral gavage; daily for 8 days) decreases AR and AR-V7 signaling and inhibits growth in a patient- derived model of lethal prostate cancer (NOD/SCID gamma (NSG) male castrated mice)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Noncastrated male athymic nude mice^[1]
Dosage:

10-30 mg/kg
Administration:

Oral gavage; at 10 or 20 mg/kg daily (QD) or at 30 mg/kg every other day (QOD) for 28 days
Result:

Affected tumor growth at 10 mg/kg daily, 20 mg/kg daily, and 30 mg/kg every other day.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 2222941-37-7
Appearance Solid
분자량 534.60
화학식 C₃₀H₃₂F₂N₄O₃
Color White to off-white
SMILES

O=C1N(C2=CC=C(F)C(F)=C2)[C@H](C3=NC4=CC(C5=C(C)ON=C5C)=CC=C4N3[C@H]6CC[C@H](OC)CC6)CCC1
Synonyms

CCS1477
선적

Room temperature in continental US; may vary elsewhere.

보관

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (12)

All Cell Proliferation/Viability AssayRT-PCRWB

Sort by:

Journal Impact Factor

Cell

p53 safeguards chemical reprogramming of human somatic cells toward pluripotency. [Abstract]

2026 Jun 11;189(12):3541-3552.e18. PMID: 41999746
Blood

Targeting Caseinolytic Mitochondrial Matrix Peptidase, a Novel Contributor to High-risk Behavior, in Multiple Myeloma. [Abstract]

2025 Feb 6:blood.2024024781. PMID: 39912779
Nat Commun

Targeting dependency on a paralog pair of CBP/p300 against de-repression of KREMEN2 in SMARCB1-deficient cancers. [Abstract]

2024 Jun 5;15(1):4770. PMID: 38839769

Inobrodib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Jun 5;15(1):4770. [Abstract]

IC50 values of the CBP/p300 inhibitors CP-C27, A-485, and Inobrodib (6 days), the EZH2 inhibitor tazemetostat, and the EZH1/EZH2 inhibitor valemetostat in HEK293T, JMU-RTK-2 +SMARCB1, and JMU-RTK-2 -SMARCB1 cells.
Adv Sci (Weinh)

BCR::ABL1-Induced Enhancer Reprogramming Uncovers Hypersensitivity of Ph+B-ALL Cells to Enhancer-Targeting Drugs. [Abstract]

2026 Mar 1:e17231. PMID: 41764406
Nucleic Acids Res

Chromatin accessibility and pioneer factor FOXA1 restrict glucocorticoid receptor action in prostate cancer. [Abstract]

2024 Jan 25;52(2):625-642. PMID: 38015476

Inobrodib purchased from MedChemExpress. Usage Cited in: Nucleic Acids Res. 2024 Jan 25;52(2):625-642. [Abstract]

Bar graphs depict KLK3 gene expression analysis in VCaP ENZ 0, VCaP ENZ 3w, 22Rv1 ENZ 0, and 22Rv1 ENZ 3w cells treated with or without Dex in the presence or absence of 0.1 or 1 μM of indicated inhibitor (A-485, CCS1477, I-BET762, BRM014).
Cell Death Dis

Oncometabolite fumarate facilitates PD-L1 expression and immune evasion in clear cell renal cell carcinoma. [Abstract]

2025 Jun 3;16(1):432. PMID: 40461489

Inobrodib purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Jun 3;16(1):432. [Abstract]

Western blot and qRT-PCR analyses were performed to evaluate the PD-L1 levels in RCC10 and RCC4 cells treated with DMF/FHIN1, both in the absence and presence of 20 μM A485 or 100 nM CCS1477, an inhibitor of p300.
J Med Chem

Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression. [Abstract]

2024 Apr 11;67(7):5275-5304. PMID: 38477974
J Med Chem

Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate Cancer. [Abstract]

2024 Apr 11;67(7):5351-5372. PMID: 38530938
EMBO Rep

p300/CBP is an essential driver of pathogenic enhancer activity and gene expression in Ewing sarcoma. [Abstract]

2025 Oct;26(19):4766-4793. PMID: 40890402

Inobrodib purchased from MedChemExpress. Usage Cited in: EMBO Rep. 2025 Oct;26(19):4766-4793. [Abstract]

RT-qPCR for eRNA of NKX2-2, CCND1 and PPP1R1A enhancers following 6 h treatment of A-485, CCS1477 (1 μM), and dCBP-1 treatment in SKNMC cells.

Inobrodib purchased from MedChemExpress. Usage Cited in: EMBO Rep. 2025 Oct;26(19):4766-4793. [Abstract]

Cell viability of SKNMC and A673 cells treated with A-485, CCS1477 (1 μM) and Dual combination for 6 days measured by CellTiter-Glo.
Cell Mol Life Sci

EP300/CREBBP acetyltransferase inhibition limits steroid receptor and FOXA1 signaling in prostate cancer cells. [Abstract]

2024 Apr 2;81(1):160. PMID: 38564048
Cancer Res Commun

Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers. [Abstract]

2025 Jan 1;5(1):24-38. PMID: 39625239
bioRxiv

2023 Mar 3.

용액&용해도

In Vitro:

DMSO : 100 mg/mL (187.06 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.8706 mL

9.3528 mL

18.7056 mL

5 mM

0.3741 mL

1.8706 mL

3.7411 mL

10 mM

0.1871 mL

0.9353 mL

1.8706 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (4.68 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (4.68 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.68 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 4

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline

Solubility: ≥ 2.5 mg/mL (4.68 mM); Clear solution

Protocol 5

Add each solvent one by one: 5% DMSO 95% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (4.68 mM); Clear solution

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

순도&문서

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Rasool RU, et al. Toppling the HAT to Treat Lethal Prostate Cancer. Cancer Discov. 2021;11(5):1011-1013. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.8706 mL	9.3528 mL	18.7056 mL	46.7639 mL
	5 mM	0.3741 mL	1.8706 mL	3.7411 mL	9.3528 mL
	10 mM	0.1871 mL	0.9353 mL	1.8706 mL	4.6764 mL
	15 mM	0.1247 mL	0.6235 mL	1.2470 mL	3.1176 mL
	20 mM	0.0935 mL	0.4676 mL	0.9353 mL	2.3382 mL
	25 mM	0.0748 mL	0.3741 mL	0.7482 mL	1.8706 mL
	30 mM	0.0624 mL	0.3118 mL	0.6235 mL	1.5588 mL
	40 mM	0.0468 mL	0.2338 mL	0.4676 mL	1.1691 mL
	50 mM	0.0374 mL	0.1871 mL	0.3741 mL	0.9353 mL
	60 mM	0.0312 mL	0.1559 mL	0.3118 mL	0.7794 mL
	80 mM	0.0234 mL	0.1169 mL	0.2338 mL	0.5845 mL
	100 mM	0.0187 mL	0.0935 mL	0.1871 mL	0.4676 mL

Keywords

Inobrodib

12 Cited Publications

100 mg 견적 받기

Subscribe to the

MedChemExpress

Newsletter

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

상품명:
CAS No.:
Species:
Purity:
수량:

Inobrodib

Epigenetics Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Drug Repurposing Compound Library

Reprogramming Compound Library

Anti-Blood Cancer Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Target Protein Ligand Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

Epigenetics Compound Library Mini

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Inobrodib

All Epigenetic Reader Domain Isoforms

All Histone Acetyltransferase Isoforms

Biological Activity

Chemical Information

Publications (12)

용액&용해도

순도&문서

References

Help & FAQs

Complete Stock Solution Preparation Table

Inobrodib

Epigenetics Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Drug Repurposing Compound Library

Reprogramming Compound Library

Anti-Blood Cancer Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Target Protein Ligand Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

Epigenetics Compound Library Mini

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Inobrodib

All Epigenetic Reader Domain Isoforms

All Histone Acetyltransferase Isoforms

Biological Activity

Chemical Information

Publications (12)

용액&용해도

순도&문서

References

Help & FAQs

Complete Stock Solution Preparation Table

Inobrodib Related Classifications

HY-111784 Related Classifications